Analyst Price Targets — BMRN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 1:26 pm | Akash Tewari | Jefferies | $103.00 | $59.86 | StreetInsider | Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign" |
| March 3, 2026 11:12 am | Eliana Merle | Barclays | $105.00 | $59.74 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays |
| March 2, 2026 2:53 pm | Ilya Zubkov | Loop Capital Markets | $105.00 | $60.47 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets |
| February 26, 2026 1:22 pm | Whitney Ijem | Canaccord Genuity | $104.00 | $60.26 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord |
| February 24, 2026 12:48 pm | — | Oppenheimer | $95.00 | $62.92 | TheFly | BioMarin price target lowered to $95 from $98 at Oppenheimer |
| February 24, 2026 11:48 am | Paul Matteis | Stifel Nicolaus | $68.00 | $61.44 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel |
| February 18, 2026 11:23 am | — | Wells Fargo | $75.00 | $59.95 | TheFly | BioMarin price target raised to $75 from $70 at Wells Fargo |
| February 6, 2026 11:51 am | — | Piper Sandler | $84.00 | $57.15 | TheFly | BioMarin price target lowered to $84 from $122 at Piper Sandler |
| January 20, 2026 10:05 am | — | Canaccord Genuity | $98.00 | $54.59 | TheFly | BioMarin upgraded to Buy from Hold at Canaccord |
| December 23, 2025 12:38 pm | Joon Lee | Truist Financial | $100.00 | $59.28 | TheFly | BioMarin price target raised to $100 from $80 at Truist |
Latest News for BMRN
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects.
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, sending its shares down 4%.
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, building on over 10,000 patient-years of data VOXZOGO is the only approved treatment for children with achondroplasia starting at birth and has the most extensive published clinical evidence, including in measures beyond…
Dimensional Fund Advisors LP grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 42.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,245,186 shares of the biotechnology company's stock after acquiring an additional 671,566 shares during the quarter. Dimensional
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BMRN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.